Research programme: K-ras gene therapies - Introgen/sanofi-aventis

Drug Profile

Research programme: K-ras gene therapies - Introgen/sanofi-aventis

Alternative Names: Antisense K-ras gene therapy -Introgen Therapeutics; IGN-111; RV-AS-K-RAS

Latest Information Update: 04 Mar 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Introgen Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Ras gene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 31 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form sanofi-aventis
  • 04 Jul 2002 This programme is still in active development
  • 24 Dec 1999 Rhône-Poulenc Rorer Gencell is now called Aventis Gencell
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top